iTeos Therapeutics, Inc. (NASDAQ:ITOS) Short Interest Update

iTeos Therapeutics, Inc. (NASDAQ:ITOS) was the recipient of a significant increase in short interest during the month of January. As of January 31st, there was short interest totalling 1,410,000 shares, an increase of 5.2% from the January 15th total of 1,340,000 shares. Based on an average daily volume of 419,500 shares, the days-to-cover ratio is presently 3.4 days. Currently, 4.6% of the company’s stock are short sold.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. Wells Fargo & Company lowered their price objective on iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating for the company in a research note on Thursday, December 19th. Wedbush reaffirmed an “outperform” rating and issued a $25.00 target price on shares of iTeos Therapeutics in a report on Friday, January 10th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $21.00 target price on shares of iTeos Therapeutics in a report on Thursday, January 16th.

Insider Transactions at iTeos Therapeutics

In related news, CFO Matthew Gall acquired 5,000 shares of the stock in a transaction dated Tuesday, November 19th. The stock was purchased at an average cost of $7.73 per share, with a total value of $38,650.00. Following the completion of the purchase, the chief financial officer now directly owns 65,429 shares in the company, valued at $505,766.17. This trade represents a 8.27 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 12.50% of the company’s stock.

Hedge Funds Weigh In On iTeos Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. nVerses Capital LLC grew its holdings in iTeos Therapeutics by 212.5% during the third quarter. nVerses Capital LLC now owns 2,500 shares of the company’s stock valued at $26,000 after purchasing an additional 1,700 shares during the period. Point72 DIFC Ltd bought a new position in iTeos Therapeutics during the third quarter valued at $31,000. Virtus ETF Advisers LLC grew its holdings in iTeos Therapeutics by 58.2% during the fourth quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company’s stock valued at $69,000 after purchasing an additional 3,293 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in iTeos Therapeutics by 60.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,024 shares of the company’s stock valued at $72,000 after purchasing an additional 2,646 shares during the period. Finally, Forefront Analytics LLC bought a new position in iTeos Therapeutics during the fourth quarter valued at $85,000. 97.16% of the stock is owned by institutional investors.

iTeos Therapeutics Trading Up 1.8 %

Shares of ITOS stock traded up $0.13 during trading on Monday, hitting $7.40. The company’s stock had a trading volume of 167,573 shares, compared to its average volume of 250,342. The business has a fifty day moving average of $7.66 and a 200-day moving average of $10.27. iTeos Therapeutics has a 52 week low of $7.06 and a 52 week high of $18.75. The company has a market cap of $270.32 million, a PE ratio of -2.35 and a beta of 1.38.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.